Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Cash Flows

v2.4.0.6
Consolidated Statements of Cash Flows (USD $)
In Thousands, unless otherwise specified
12 Months Ended
Dec. 31, 2011
Dec. 31, 2010
Dec. 31, 2009
Operating activities      
Net income $ 132,582 $ 149,663 $ 100,756
Adjustments to reconcile net income to cash provided by operating activities:      
Depreciation 150,149 138,637 144,055
Amortization of intangible and other assets and unfavorable leases 4,300 4,871 5,460
Amortization of long-term prepaid rents 2,657 1,786 1,389
Amortization of debt issue costs 4,744 4,716 4,775
Amortization of deferred revenues, deferred lease incentives and other (9,629) (6,968) (4,810)
Amortization of bond discount 853 780 365
Amortization of accumulated other comprehensive loss related to interest rate swap agreement 4,236 4,633 4,633
Fair value change in interest rate swap agreements not designated as hedges (1,130)    
Impairment of long-lived assets 7,033 12,538 11,858
Share based awards compensation expense 9,692 8,352 4,304
(Gain) loss on sale of assets and other 7,754 (2,464) 3,202
Loss on contribution and sale of digital projection systems to DCIP 1,038 2,033  
Loss on marketable securities - RealD 12,610    
Loss on early retirement of debt 4,943   6,337
Accretion of interest on senior discount notes     8,085
Deferred lease expenses 4,155 3,940 3,960
Deferred income tax expenses 21,676 (8,603) (12,614)
Equity in (income) loss of affiliates (5,651) 3,438 907
Interest paid on repurchased senior discount notes     (158,349)
Tax benefit related to stock option exercises and restricted stock vesting 917 2,680 7,545
Increase in deferred revenue related to new U.S. beverage agreement     6,550
Distributions from equity investees 7,125 5,486 2,699
Changes in other assets and liabilities 31,148 (60,767) 35,656
Net cash provided by operating activities 391,201 264,751 176,763
Investing activities      
Additions to theatre properties and equipment (184,819) (156,102) (124,797)
Proceeds from sale of theatre properties and equipment and other 6,230 21,791 2,178
Investment in DCIP and other (1,520) (1,756) (2,500)
Net cash used for investing activities (247,067) (136,067) (183,130)
Financing activities      
Proceeds from stock option exercises 444 7,914 2,524
Payroll taxes paid as a result of noncash stock option exercises and restricted stock withholdings (494) (416) (8,972)
Dividends paid to stockholders (95,838) (84,502) (78,643)
Retirement of senior discount notes     (261,054)
Retirement of senior subordinated notes   (181)  
Proceeds from issuance of senior notes     458,532
Proceeds from issuance of senior subordinated notes 200,000    
Payment of debt issue costs (4,539) (8,858) (13,003)
Repayments of other long-term debt (166,898) (11,853) (12,605)
Payments on capital leases (7,526) (7,327) (6,064)
Purchases of noncontrolling interest (1,443) (888)  
Other (2,120) (539) (2,416)
Net cash provided by (used for) financing activities (78,414) (106,650) 78,299
Effect of exchange rates on cash and cash equivalents (9,309) 5,027 16,401
Increase in cash and cash equivalents 56,411 27,061 88,333
Cash and cash equivalents:      
Beginning of period 464,997 437,936 349,603
End of period 521,408 464,997 437,936
U S
     
Investing activities      
Acquisition of theatres in the U.S., Brazil and theatres in Argentina 0   (48,950)
B R
     
Investing activities      
Acquisition of theatres in the U.S., Brazil and theatres in Argentina 0   (9,061)
ARGENTINA
     
Investing activities      
Acquisition of theatres in the U.S., Brazil and theatres in Argentina $ (66,958)